Distribution of CYP2C19 polymorphisms in Mongolian and Han nationals and the choice of specific antiplatelet drugs

• Published in: International journal of clinical pharmacy Vol. 39; no. 4; pp. 791 - 797
• Main Authors: Li, Jing, Wang, YueXi, Wang, HuPing
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2017; Springer Nature B.V
• Subjects: Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - genetics; Acute Coronary Syndrome - surgery; Acute coronary syndromes; Adult; Aged; Asian Continental Ancestry Group - genetics; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19 - genetics; Drug therapy; Female; Follow-Up Studies; Genotypes; Humans; Incidence; Internal Medicine; Male; Medicine; Medicine & Public Health; Metabolism; Middle Aged; Percutaneous Coronary Intervention - trends; Pharmacy; Platelet Aggregation Inhibitors - therapeutic use; Polymorphism, Single Nucleotide - genetics; Prospective Studies; Research Article; Side effects; Clopidogrel; Mongolia; Pharmacogenetics; Acute coronary syndrome; Ticagrelor; polymorphisms; CYP2C19 polymorphisms
• ISSN: 2210-7703; 2210-7711
• DOI: 10.1007/s11096-017-0451-5

Background Individualized medication reviews may improve our understanding of the distribution of CYP2C19 polymorphisms in ethnic populations. Objective To evaluate differences in CYP2C19 gene polymorphisms between Mongolian and Han nationals and determine the effect of adjustments of antiplatelet treatments according to the genetic profile in patients undergoing percutaneous coronary intervention (PCI). Setting Prospective, observational, single-center study. Methods 397 patients diagnosed with acute coronary syndrome were enrolled. Additionally, 186 patients undergoing PCI were given different treatments according to their CYP2C19 genotypes. Patients with the genotype of an extensive metabolizers (EMs; *1/*1) were co-administered aspirin 100 mg/day and clopidogrel 75 mg/day, following a loading dose of 300 mg; intermediate metabolizers (IMs; e.g., *1/*2 and *1/*3) and poor metabolizers (PMs; e.g., *2/*2 and *2/*3) were administered a loading dose of 180 mg ticagrelor, followed by a maintenance dose of 90 mg twice a day. Results In Mongolians, 60.79% of patients were EMs, which was significantly higher than that in Han nationals ( P  = 0.002). In Han individuals, 62.14% of patients were IMs and PMs, which was significantly higher than that in Mongolians ( P  < 0.05). Three patients died, and the frequency of adverse events during follow-up was significantly higher in patients given conventional treatment than in patients given tailored treatment ( P  = 0.039). However, differences in metabolism subtypes did not affect the incidence of adverse reactions. Conclusions There were differences in CYP2C19 polymorphisms between Mongolians and Hans. Effective, safe therapy was achieved by tailoring antiplatelet drug therapy based on genotype.